201. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.
- Author
-
Dan Huang, Ning Lu, Qinhe Fan, Weiqi Sheng, Hong Bu, Xiaolong Jin, Guimei Li, Yanhui Liu, Xianghong Li, Wenyong Sun, Huizhong Zhang, Xiaobing Li, Zongguang Zhou, Min Yan, Xuan Wang, Weihong Sha, Jiafu Ji, Xiangdong Cheng, Zhiwei Zhou, Jianming Xu, and Xiang Du
- Subjects
Medicine ,Science - Abstract
Trastuzumab has been approved for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction cancers (GC and GJC) in combination with chemotherapy. The aim of this HER2 early/advanced gastric epidemiology (HER-EAGLE) study was to evaluate the frequency of HER2 over-expression and to evaluate agreement on HER2 status assessment in GC and GJC patients in local laboratories versus a central laboratory in China. Tumor samples from 734 GC or GJC patients who were enrolled at 11 different hospitals in China were examined. HER2 status was assessed by immunohistochemistry (IHC), and followed by dual-color silver-enhanced in Situ hybridization (DSISH) in IHC 2+ cases. Clinicopathologic characteristics were collected from all of the patients. HER2-positive tumors were identified in 12.0% (88/734) of the GC and GJC cases. There were significantly higher rates of HER2 positivity in patients with GJC (GJC: 18.1%, GC: 9.7%, P=0.002), and intestinal-type cancers using the Lauren classification (intestinal: 23.6%, diffuse/mixed: 4.3%, P
- Published
- 2013
- Full Text
- View/download PDF